What is Mindtension?
Mindtension is developing an affordable, ultra-precise, and rapid diagnostic platform designed to measure Attention Deficit Hyperactivity Disorder (ADHD). The company addresses a significant challenge in the medical field, where diagnosing ADHD and subsequently prescribing accurate medication is often an inexact science. Inaccurate dosages can lead to severe behavioral challenges and patient anguish. Mindtension aims to bring a data-driven approach to this complex diagnostic process, potentially revolutionizing how ADHD is identified and managed.
How much funding has Mindtension raised?
Mindtension has raised a total of $2M across 1 funding round:
Angel/Seed
$2M
Angel/Seed (2023): $2M with participation from Galia Kut, Arazim, and Israeli Innovation Authority
Key Investors in Mindtension
Arazim
Arazim specializes in high-quality products and services in the fields of data acquisition systems, navigation and GPS, semiconductors, sensors, timing and synchronization, and wireless systems. With over 30 years of industry experience, they offer customized solutions and on-site technical support to meet client needs. Their intended clients include those in the medical instrumentation and digital health sectors, as evidenced by their participation in industry events like MDI EXPO 2025. The company is committed to delivering excellence at competitive prices.
What's next for Mindtension?
With the recent major strategic investment, Mindtension is poised for significant expansion. The enterprise-level funding context suggests the company is moving beyond early-stage development and is likely focusing on scaling its operations, refining its diagnostic technology, and potentially initiating broader clinical trials or market penetration strategies. This backing will be crucial for enhancing the platform's capabilities and establishing its position as a leader in digital health solutions for neurological disorders.
See full Mindtension company page
